The past few years have been challenging for the biotech.
Hosted on MSN
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?
The global cell therapy market was valued at $5.88 billion in 2024 and is on track to hit $44.39 billion by 2034, expanding at a striking 22.69% CAGR. Researchers credit this explosive growth to ...
In this article, we will take a look at the 9 Best Gene-Editing Stocks to Buy According to Hedge Funds. Genetic manipulation – or gene editing – is a concept that describes altering the genetic ...
Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes ...
Another place to seek out potentially explosive stocks is in the biotech space. These innovators are working on the ...
The MarketWatch News Department was not involved in the creation of this content. Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /CNW/ -- Equity Insider News Commentary -- The ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, RBC Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP ...
Beam Therapeutics is one of the few biotechs that has shown immense potential in the gene therapy space. The company’s proprietary base-editing technology potentially enables the development of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results